Algert Global LLC Aerie Pharmaceuticals Inc Transaction History

Algert Global LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$6.37 - $15.23 $90,269 - $215,824	-14,171 Reduced 48.14%	15,269 $231,000
Q2 2022 Aug 15, 2022	BUY	$4.95 - $9.16 $145,728 - $269,670	29,440 New	29,440 $221,000
Q1 2022 May 16, 2022	SELL	$5.64 - $9.8 $85,914 - $149,283	-15,233 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.02 - $13.33 $23,236 - $44,122	-3,310 Reduced 17.85%	15,233 $107,000
Q3 2021 Nov 15, 2021	SELL	$11.32 - $16.63 $30,756 - $45,183	-2,717 Reduced 12.78%	18,543 $211,000

Q2 2021 Aug 13, 2021	BUY	$15.16 - $18.97 $67,765 - $84,795	4,470 Added 26.62%	21,260 $340,000
Q1 2021 May 14, 2021	BUY	$13.12 - $20.9 $58,515 - $93,214	4,460 Added 36.17%	16,790 $300,000
Q4 2020 Feb 12, 2021	BUY	$9.12 - $14.49 $112,449 - $178,661	12,330 New	12,330 $167,000
Q3 2020 Nov 16, 2020	SELL	$10.46 - $14.46 $126,461 - $174,821	-12,090 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$12.0 - $16.13 $18,420 - $24,759	-1,535 Reduced 11.27%	12,090 $178,000
Q1 2020 May 13, 2020	BUY	$11.84 - $25.52 $161,320 - $347,710	13,625 New	13,625 $184,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.